NGY 091
Alternative Names: NGY-091Latest Information Update: 22 Jan 2023
Price :
$50 *
At a glance
- Originator Nirogy Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Monocarboxylic acid transporter inhibitors; Solute carrier protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Dec 2022 Preclinical trials in Cancer in USA (PO) Before December 2022 (Nirogy therapeutics pipeline, December 2022)
- 06 Dec 2022 Preclinical pharmacodynamic data in Cancer presented at the 45th Annual San Antonio Breast Cancer Symposium
- 26 Oct 2022 Pharmacodynamics data from a preclinical trial in Cancer presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)